about
The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug usersRapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysisThe cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studiesInnovative financing for HIV response in sub-Saharan AfricaFinancing essential HIV services: a new economic agenda.The determinants of technical efficiency of a large scale HIV prevention project: application of the DEA double bootstrap using panel data from the Indian AvahanIs there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.The impact of HIV/SRH service integration on workload: analysis from the Integra Initiative in two African settings.The costs of scaling up HIV prevention for high risk groups: lessons learned from the Avahan Programme in IndiaThe costs of HIV prevention for different target populations in Mumbai, Thane and Bangalore.Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study.Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysis.Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countriesStudy protocol for the Integra Initiative to assess the benefits and costs of integrating sexual and reproductive health and HIV services in Kenya and Swaziland.Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysisEvaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial.Evaluating the effect of innovative motivation and supervision approaches on community health worker performance and retention in Uganda and Mozambique: study protocol for a randomised controlled trial.Tuberculosis retreatment 'others' in comparison with classical retreatment cases; a retrospective cohort review.Use of HIV counseling and testing and family planning services among postpartum women in Kenya: a multicentre, non-randomised trial.Innovation in Evaluating the Impact of Integrated Service-Delivery: The Integra Indexes of HIV and Reproductive Health Integration.Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services.Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners.Valuing the work of unpaid community health workers and exploring the incentives to volunteering in rural AfricaDoes integration of HIV and sexual and reproductive health services improve technical efficiency in Kenya and Swaziland? An application of a two-stage semi parametric approach incorporating quality measuresPositive impact of a large-scale HIV prevention programme among female sex workers and clients in South India.The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda.What Determines HIV Prevention Costs at Scale? Evidence from the Avahan Programme in India.Tracking aid flows for development assistance for healthA clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South AfricaCost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India.Is Development Assistance for Health fungible? Findings from a mixed methods case study in Tanzania.When an emerging disease becomes endemic.Cost-Effectiveness Thresholds in Global Health: Taking a Multisectoral Perspective.Financing structural interventions: going beyond HIV-only value for money assessments.Financing tuberculosis control: promising trends and remaining challenges.Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.Secondary schooling might be as good an HIV investment as male circumcision.
P50
Q27022255-BE13CFA0-6F3E-4CFD-8629-25804CF86D38Q28476518-A5D9C651-5B06-49AA-A9EB-3B7336AEB8BFQ28477855-B9CE85C8-1C91-415B-A0DB-3177FEF20550Q28487926-61ECB481-4A51-4441-B563-FF901C80C96AQ30384504-F463ED53-8DD8-4700-8D5A-9CDB42E47D3CQ30392651-7CADEEE8-DAC2-4C8D-ACFF-BBFCDD91D9C7Q30636965-B41996AE-047C-43EA-B1AF-A42343B524FAQ34002707-DF7409C5-9A1A-48DF-BC60-3880DC3182FEQ34034608-F835F12F-2555-4965-B89C-F9E5198DF904Q34155879-C919D3B8-EA1C-4412-8D06-5445A33D9F55Q34178473-66CEA0FA-F51D-4AB0-BC66-53749725D45EQ34373838-9B800A41-AA98-44EB-9932-22D870BB9E0BQ34379703-68052EF4-85FA-4316-B30D-7C16AD1EAC8AQ34441930-F526E249-684B-4C1E-86E5-DD8B6CDDBBA7Q34475495-B3DA4AB1-BC15-4CAA-92B6-1FCF91AC099AQ35075418-83E31AAB-3DFD-4266-AD35-AC686FFEEF79Q35382585-06996C55-6DB1-4376-B246-03CCA0D14D50Q35610077-FEC91929-0D15-4959-B1D9-7E9EC761172AQ35761800-171C5A3B-6FFF-4252-907E-3451ADD8C663Q35840169-A09EB868-AB2E-46A2-91CC-7D7016145CE9Q35901818-D03C4275-0C68-4A3E-A248-91F01002563BQ35901882-2562BB76-7304-41D8-B579-60360D4502EDQ36358537-05947BBD-E23A-4723-90DD-DD127FEBE784Q36564743-C5C5DC17-E8CF-476E-A4F0-772664961460Q36640348-08F5D2F6-917B-45EB-96DD-B769A8FF247EQ36919446-88ADF101-F3F6-48A3-90BD-96693429DB82Q37152605-D9702760-622F-445E-B52A-748DDC23AE53Q37248645-A2C7B54C-8559-4FD8-B5AC-55BADF526666Q37587166-9FC8ABB4-892C-4E6C-9947-F646541160DDQ38644445-6972176C-67DD-48D8-B507-557FB36606BCQ38859476-9E4794F4-DDC9-4CE9-BDDB-BAA2D87CC41FQ38947214-EE6336E0-B9C4-4D6B-91FF-3865559DF236Q39115347-FB33D3FE-3AAC-47D6-9FC7-BF6F7CA90500Q39220760-2C6443DF-6D0E-460D-96BF-66BBE5934623Q39239989-3D25B7B3-A73B-46E5-9606-ED2A3CD0EACDQ39392323-77CC07A0-62BE-4D7E-8A7D-0281C2082CF2Q39392336-4D98AE65-361F-447B-905C-9888E31351E1Q39555089-B10FD3E6-8A66-449F-879C-C1309D5F2570Q41572739-B4B7230E-A0C0-4998-A97F-9C87D3173FB3Q43414880-0A2120AC-7107-4FAE-B27B-8B796BBAC78E
P50
name
Anna Vassall
@en
Anna Vassall
@nl
type
label
Anna Vassall
@en
Anna Vassall
@nl
prefLabel
Anna Vassall
@en
Anna Vassall
@nl